Compare Oruka Therapeutics Inc. Common Stock (ORKA) vs ZIM Integrated Shipping Services Ltd (ZIM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oruka Therapeutics Inc. Common Stock vs ZIM Integrated Shipping Services Ltd — how do they compare? Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.08B), while ZIM Integrated Shipping Services Ltd trades at $29.85 (market cap $3.60B). The key difference: Oruka Therapeutics Inc. Common Stock is the larger of the two by market cap, and ZIM Integrated Shipping Services Ltd pays a 20.16% dividend while Oruka Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oruka Therapeutics Inc. Common Stock for 0 Days and ZIM Integrated Shipping Services Ltd for 23 Days on average.
| ORKA | ZIM | |
|---|---|---|
Market Cap | $5.08B | $3.60B |
Volume | 685,276 | 1,141,549 |
Sector | Health | Industrials |
52-Week High | $113.08 | $30.90 |
52-Week Low | $26.19 | $13.32 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $4.21B | $7.27B |
Dividend Yield | — | 20.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ZIM trades at $30.43, down 1.52% on the day, but remains near its 52-week high of $30.96. The stock shows strong technical momentum with bullish moving averages and recent earnings beats. Fundamentally, ZIM reported Q2 2026 revenue growth of 9% to $1.8 billion and net income up 170% to $64 million, though full-year 2026 guidance indicates margin compression. The pending $35 per share acquisition offer from Hapag-Lloyd creates significant upside potential but faces regulatory uncertainty from Israeli government review.
ZIM presents a mixed investment case with acquisition-driven upside countered by operational challenges. The $35 takeover bid offers 15% premium to current levels, while strong transpacific rates and LNG fleet modernization support fundamentals. However, declining profit margins, negative cash flow, and regulatory hurdles create substantial risk. Analyst consensus remains cautious with 67% hold ratings, reflecting the binary outcome between acquisition success and standalone operational pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →About ZIM Integrated Shipping Services Ltd
ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →
